MRK vs TECH
MRK: Merck & Co. is a leading global biopharmaceutical firm dedicated to delivering life-saving vaccines and innovative therapeutic medicines for major disease areas. TECH: Bio-Techne provides the essential tools, reagents, and instruments fueling scientific discovery, advanced diagnostics, and cell and gene therapy manufacturing.
Side-by-side fundamentals
| Metric | MRK | TECH | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $152.55 | $72.32 | |
| Market cap as of 2026-08-24 | $376.4B | $11.3B | |
| P/E as of 2026-08-24 | 103.86 | 104.27 | MRK lower |
| PEG as of 2026-08-24 | 4.91 | 16.36 | MRK lower |
| Net margin as of 2026-08-24 | +4.8% | +9.0% | TECH higher |
| Gross margin as of 2026-08-24 | +77.3% | +66.4% | MRK higher |
| Operating margin as of 2026-08-24 | +9.6% | +12.7% | TECH higher |
| ROE as of 2026-08-24 | +17.9% | +5.4% | MRK higher |
| ROA as of 2026-08-24 | +7.0% | +4.3% | MRK higher |
| Debt / equity as of 2026-08-24 | 1.07 | 0.10 | TECH lower |
| Revenue growth (YoY) as of 2026-08-24 | +4.6% | +0.2% | MRK higher |
| Revenue CAGR (3y) SEC XBRL | +3.1% | +3.3% | TECH higher |
| Dividend yield as of 2026-08-24 | +2.9% | +0.5% | MRK higher |
| Dividend streak (yrs) SEC XBRL | 5 | 5 | Tie |
| Beta as of 2026-08-24 | 0.22 | 1.30 | |
| 1-year return as of 2026-08-21 close | +77.2% | +33.9% | MRK higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.